SCHEMBL10116707

SCHEMBL10116707

Cc1cc(C(=O)NC(C)C)c(C)c(C)c1NC(=O)c1ccc(NS(=O)(=O)C(C)C)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACLY P53396 1/20 0.40
MAPT P10636 4/20 0.40
LMNA P02545 3/20 0.40
KDM4E B2RXH2 3/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
ALDH1A1 P00352 5/20 0.39
EPHX2 P34913 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
MAP1LC3B Q9GZQ8 1/20 0.37
MAP1LC3A Q9H492 1/20 0.37
HPGD P15428 5/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
MAPK10 P53779 1/20 0.36
HTT P42858 2/20 0.36
MAPK1 P28482 1/20 0.36
GRIA2 P42262 1/20 0.35
GRIA4 P48058 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10116402 0.87 LMNA (0.43) ACLYMAPTLMNAKDM4EMEN1
SCHEMBL14596583 0.86 ACLY (0.46) ACLYMAPTLMNAKDM4EMEN1
SCHEMBL10116713 0.85 ALDH1A1 (0.43) ACLYMAPTLMNAKDM4EMEN1
SCHEMBL17090477 0.83 PPARA (0.38) ACLYLMNAALDH1A1EPHX2NR1H4
SCHEMBL10116717 0.82 HPGD (0.41) ACLYMAPTLMNAKDM4EMEN1
SCHEMBL10116627 0.79 LMNA (0.56) ACLYMAPTLMNAKDM4EMEN1
SCHEMBL10116589 0.79 HPGD (0.49) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL10116728 0.78 MAPT (0.46) ACLYMAPTLMNAKDM4EMEN1
SCHEMBL10116611 0.76 ACLY (0.45) ACLYMAPTLMNAKDM4EMEN1
SCHEMBL10116568 0.74 HPGD (0.58) MAPTKDM4EMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R ACLY 3437/4885MAPT 3367/4885LMNA 2068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.